[ad_1]
NEW YORK — A consensus could also be rising about how one can prescribe the brand new Alzheimer’s drug lecanemab, in line with remarks made by each a critic of different Alzheimer’s medicines and the CEO of the corporate that developed it.
Ivan Cheung, the CEO of Eisai, the lecanemab developer, stated at a STAT occasion Monday night time that if sufferers carry a specific genetic variant that will increase the danger of bleeding within the mind when taking the drug, they need to solely take the medication in the event that they and their households are prepared to submit to shut monitoring from medical doctors.
[ad_2]
Source link